Annovis Q2 Loss Widens to $0.40/Share as R&D Spend Doubles; Cash at $18.7M
ANVS sits 16% above its 52-week low of $1.541.
Summary
Annovis reported Q2 2026 results with a net loss of $0.40 per share, up from $0.32 a year ago, as R&D expenses more than doubled to $12.0 million. Cash stands at $18.7 million, down from $19.5 million at year-end 2025, with 42.6 million shares outstanding. The company reiterated that topline data from its fully enrolled Phase 3 Alzheimer's trial is expected in Q1 2027, with a database lock planned for that quarter. Management also promoted Cheng Fang to Chief Scientific Officer and provided updates on open-label extension studies for both Alzheimer's and Parkinson's. The widening loss and modest cash position underscore the company's ongoing reliance on dilutive financing, though the Phase 3 readout remains the primary value driver.
At the time of this announcement, ANVS was trading at $1.79 on NYSE in the Life Sciences sector, with a market capitalization of approximately $76.1M. The 52-week trading range was $1.54 to $5.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.